Citations

Clear

35 citation(s) found for "Smits, P".

BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions
Schreck, Karisa C, Fuente, Macarena I de la, Fat, Mary Jane Lim, Maas, S L, Levy, Jean M Mulcahy, Lombardi, G , Perrault, Sébastien, Petritsch, Claudia , Aldape, Kenneth, Chang, Susan M, Holdhoff, Matthias, Kazda, Tomas, Rhun, Emilie Le, Minniti, Giuseppe, Mueller, Sabine, Preusser, M, Smits, Marion, Weller, Michael, Wen, Patrick Y, Bent, Martin van den, Geurts, Marjolein, Lombardi, Giuseppe , Maas, Sybren L. N. , Schreck, Karisa C. , Levy, Jean M. Mulcahy , Chang, Susan M. , Duerinck, Johnny , Holdhoff, Matthias , Kazda, Tomáš , Rhun, Émilie Le , Minniti, Giuseppe , Mishra, Mark V. , Mueller, Sabine , Padovan, Marta , Preusser, Matthias , Smits, Marion , Weller, Michael , Bent, Martin J. van den , Geurts, Marjolein

Mayo Clinic

Neuro-Oncology | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noag135 | PMID 42261252 Get It

Abstract Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics. In addition to standard glioma therapies, targeted treatments are available for patients with BRAF-altered glioma supported by variable evidence spanning randomized trials, single-arm studies, and real-world evidence. This joint consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) synthesizes current knowledge on the diagnosis and management of BRAF-altered gliomas across age groups, tumor grades, and lines of therapy. Particular emphasis is placed on expert consensus in clinical scenarios where high-quality trial evidence remains limited. The review addresses rationale testing for BRAF alterations, selection, and monitoring of targeted therapies, management of treatment-related toxicities, approaches to resistance, and priorities for future research. It aims to provide practical, evidence-based guidance for clinicians while highlighting gaps to inform prospective studies.
ABSTRACT NUMBER: ESOC2026A145 RESIDUAL CALCIUM DENSITY REFLECTS PLAQUE VULNERABILITY AND CEREBROVASCULAR EVENT RISK IN SYMPTOMATIC CAROTID ARTERY DISEASE
Bos, Daniel, Nederkoorn, Paul, Jong, P A De, Oostenbrugge, Robert van, Song, Jae, Lanzino, Giuseppe, Kooi, M Eline, Saba, Luca, Bierens, Juul , Bos, Daniël , Nederkoorn, Paul J. , Jong, Pim A. de , Oostenbrugge, Robert J. van , Smits, Luc J.M. , Lanzino, Giuseppe , Kooi, M. Eline , Saba, Luca

Mayo Clinic

European Stroke Journal | May 6, 2026 | Volume: 11 | Issue: Supplement_1 | Pages: i120-i121

10.1093/esj/aakag023.196 Get It

Abstract Background and aims Carotid calcification features are readily quantifiable by CTA, yet their relationship with plaque vulnerability and rupture remains controversial. We investigated whether calcium score, volume, density, and residual (volume-normalized) calcium density are associated with carotid plaque vulnerability, symptomatic status, and recurrent ipsilateral ischemic stroke and transient ischemic attack (TIA). Methods Patients with recent TIA or ischemic stroke and ≥2mm carotid plaque with <70% stenosis underwent baseline CTA and MRI. Carotid calcifications were segmented on CTA (≥130 Hounsfield units), yielding calcium score, volume, and density. Volume-normalized residual calcium density was calculated as the standardized residuals from a log-transformed calcium density-volume model (Figure 1). Vulnerable plaque features (intraplaque hemorrhage, thin-or-ruptured fibrous cap, and lipid-rich necrotic core, and ulceration) were linked to calcium metrics. Associations between calcium metrics and recurrent ipsilateral TIA or ischemic stroke were assessed using Cox regression and adjusted for age, sex, stenosis. Results Among 193 patients (mean age 67.8±8.5 years, 144 (75%) men), 26 experienced ipsilateral ischemic stroke or TIA over median 5-year follow-up. Lower calcium density and residual calcium density were independently associated with vulnerable plaques (adjusted ORs: 0.40-0.60; Figure 2). Residual calcium density remained independently associated with symptomatic side (adjusted OR: 0.64, 95%CI: 0.47-0.88) and with recurrent TIA/stroke (adjusted HR: 0.53, 95%CI: 0.29-0.95). Calcium score, volume, and density were not independently associated with symptomatic side or recurrent events (Figure 3). Conclusions Residual calcium density is a robust, independent marker of carotid plaque vulnerability and ipsilateral ischemic stroke and TIA risk in patients with symptomatic carotid artery disease. Conflict of interest Juul Bierens: nothing to disclose; Daniel Bos: nothing to disclose; Paul J. Nederkoorn: nothing to disclose; Pim A. de Jong: nothing to disclose; Robert J. van Oostenbrugge: nothing to disclose; Luc J.M. Smits: nothing to disclose; Jae W. Song: nothing to disclose; Giuseppe Lanzino: nothing to disclose; M. Eline Kooi: nothing to disclose; Luca Saba: nothing to disclose. Figure 1 - belongs to Methods Figure 2 - belongs to Results Figure 3 - belongs to Conclusions
International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG
Marchegiani, Giovanni, Hegyi, Peter, Archibugi, Livia, Valente, Roberto, Capurso, Gabriele, Witt, Heiko, Bonovas, Stefanos , Maisonneuve, Patrick, Verbeke, Caroline S., Dominguez‐Muñoz, J. Enrique, Scheers, Isabelle, Czakó, László, Wagner, R, Rebours, Vinciane, Öhlund, Daniel, Gubergrits, N. B. , Engjom, Trond , Neeße, Albrecht , Apte, Minoti V. , Braren, Rickmer, Bunduc, Stefania, Ceyhan, Güralp Onur, Chouhan, Manil Dinesh, Couvelard, Anne, Iglesia, Daniel de la, Drewes, Asbjørn Mohr, Sarasqueta, A. Farina, Francque, Sven, Frøkjær, Jens Brøndum, Iglesias‐Garcia, Julio, Garg, Pramod, Gerst, Felicia, Gulbinas, Antanas, Gürcinar, Ibrahim Halil, Heni, Martin , Jonas, E G, Kitano, M., Krag, Aleksander, Laukkarinen, J., Lipp, Mónika, Loveček, M., Martignoni, Marc E., Masip, Etna , Matsumoto, Ryotaro , Mozhynа, T. L. , Nosáková, Lenka, Ockenga, Johann , Pandanaboyana, Sanjay, Panić, Nikola , Papachristou, Georgios, Pasqua, Analía V. , Pawlak, Katarzyna Monika, Regel, Ivonne , Regnér, Sara, Singh, Vijay Kumar , Smits, M., Sung, Min Je , Tacelli, Matteo, Teutsch, Brigitta, Udrescu, Mihaela, Wilschanski, Michael , Yavas, Aslihan, Zamboni, G., Löhr, J. Matthias, Singh, Vijay , Drewes, Asbjørn Mohr , Regnér, Sara , Krag, Aleksander , Marchegiani, Giovanni , Pawlak, Katarzyna M. , Marchegiani, Giovanni , Hegyi, Peter , Archibugi, Livia , Bonovas, Stefanos , Verbeke, Caroline S , de-Madaria, Enrique , Wagner, Robert , Rebours, Vinciane , Öhlund, Daniel , Neesse, Albrecht , Bezmarević, Mihailo , Bunduc, Stefania , Iglesia, Daniel de la , Drenth, Joost P H , Gürcinar, Ibrahim Halil , Jonas, Eduard , Kitano, Masayuki , Obmann, Verena , Pandanaboyana, Sanjay , Pasqua, Analia Verónica , Pawlak, Katarzyna M , Regnér, Sara , Seicean, Andrada , Sung, Min Je , Taylor, Roy , Singh, Vijay P , Krag, Aleksander , Vujasinović, Miroslav , Demir, İhsan Ekin , Hegyi, Péter , Valente, Roberto, Capurso, Gabriele , Piovani, Daniele , Rosendahl, Jonas , Maisonneuve, Patrick , Karçaaltıncaba, Muşturay , Domínguez‐Muñoz, J. Enrique , Scheers, Isabelle , Czakó, László , Idılman, Ilkay S. , Overbeek, Kasper A. , Braren, Rickmer , Chouhan, Manil Dinesh , Couvelard, Anne , Cros, Jerome F. , de‐Madaria, Enrique , Drenth, Joost P.H. , Fracasso, Pierluigi , Francque, Sven , Frøkjær, Jens Brøndum , Iglesias‐García, Julio , Garg, Pramod, Gulbinas, Antanas , Hyun, Jong Jin , Jonas, Eduard , Kiriukova, Mariia A. , Laukkarinen, Johanna , Loveček, Martin , Molven, Anders , Nosáková, Lenka , Obmann, Verena Carola , Papachristou, Georgios I. , Peláez‐Luna, Mario , Robinson, Stuart Michael , Smits, Mark M. , Tacelli, Matteo , Teutsch, Brigitta , Udrescu, Mihaela, Yavas, Aslihan , Zamboni, Giulia Angela, Löhr, J.-Matthias

Mayo Clinic

United European Gastroenterology Journal | February 14, 2026 | Volume: 14 | Issue: 1 | Pages: No page available

10.1002/ueg2.70185 | PMID 41689768 Get It

ABSTRACT This international, multidisciplinary consensus report represents the first effort to systematically define and characterize fatty pancreas. A key outcome of this endeavor was the recommendation to adopt “fatty pancreas” as the standardized and inclusive term to describe all forms of fat accumulation in the pancreas. This terminological consensus provides a critical foundation for unified reporting and clinical communication. Another major contribution of the report is the consensus on diagnostic imaging findings, which was based on radiological and endoscopic modalities. The proposed criteria aim to enhance consistency in clinical assessment and support the development of standardized research protocols. In addition to establishing terminology and diagnostic frameworks, the report also synthesizes current knowledge across a wide range of relevant domains. These include the etiology and epidemiology of fatty pancreas, as well as its associations with alcohol consumption, smoking, acute and chronic pancreatitis, pancreatic exocrine insufficiency, type 2 diabetes mellitus, and surgical outcomes. The potential links between fatty pancreas and neoplastic conditions such as intraductal papillary mucinous neoplasms and pancreatic cancer are also addressed, alongside the current understanding of its metabolic implications (beta‐cell function and glucose homeostasis) and treatment strategies. Throughout the consensus process, a consistent theme emerged: the limited availability of high‐quality, prospective clinical data. Therefore, many of the recommendations in this report are based on expert consensus rather than strong empirical evidence. As such, the statements require rigorous prospective validation before they can be adopted into routine clinical practice. This underscores a critical need for further research, particularly studies aimed at clarifying causal relationships, validating diagnostic tools, and determining the clinical relevance of fatty pancreas across diverse patient populations. This report serves as both a summary of our current understanding and a roadmap for future investigations, aiming to close existing knowledge gaps and guide evidence‐based clinical practice in this emerging field.
Small and Stable Pancreatic Cysts Are Reassuring During Surveillance: Results From the PACYFIC Trial
Levink, Iris J. M. , Sprij, Marloes L. J. A. , Koopmann, Brechtje D.M. , Meziani, Jihane , Jaarsma, Sanne, Riet, Priscilla A. van , Overbeek, Kasper A. , Gorris, Myrte , Voermans, Rogier P. , Casadei, Riccardo , Hoogenboom, Sanne A. , Azopardi, Neville, Polkowski, Marcin , Honkoop, Pieter, Schoon, Erik J. , Venneman, Niels G. , Waaij, Laurens A. van der, Berkel, Anne‐Marie van, Rossi, Gemma , Bergmann, Jilling F., Pando, Elizabeth , Schwartz, Matthijs P. , Vilsteren, Frederike G.I. van , Hoge, Chantal , Smits, Marianne E., Soest, Ellert J. van, Vos, Patrick M., Steinhauser, Toon, Kouw, Eva, Tan, Adriaan C.I.T.L. , Czakó, László , Bruno, Marco J. , Cahen, Djuna L. , Group, PACYFIC‐Study Work, Quispel, Rutger , Verdonk, Robert C , Voermans, Rogier P , Hooft, Jeanin E. van , Casadei, Riccardo , Marco, Mariacristina Di , Wallace, Michael B. , Ahola, Reea , Carrara, Silvia , Bergmann, Jilling F., Beyer, Georg , Group, PACYFIC‐Study Work

Mayo Clinic

United European Gastroenterology Journal | June 18, 2025 | Volume: 13 | Issue: 6 | Pages: 971-981

10.1002/ueg2.70043 | PMID 40530613 Get It

ABSTRACTBackgroundPancreatic cysts are increasingly discovered on imaging studies performed for unrelated conditions. Currently, surveillance of these lesions poses a substantial burden on patients, and health care recourses. We hypothesized that individuals with small and stable cysts have a diminutive risk of progressing to high‐grade dysplasia (HGD) or pancreatic cancer (PC) that is similar to that in the general population.MethodsThis nested PACYFIC‐study is a collaboration among 44 centers in Europe and Northern‐America, and investigates the risk of HGD and PC for different cyst sizes and growth rates in participants without baseline worrisome features (WF) or high‐risk stigmata (HRS).ResultsOf the 2369 PACYFIC participants, 975 met the inclusion criteria, with a mean age of 67 years (SD 13) and 65% being female. Of these, 438 individuals (45%) had a baseline small cyst size (< 15 mm), and 885 (91%) individuals had a slow growth rate (< 2.5 mm/year). During a median follow‐up of 45 months (IQR 27), 20 individuals (2.1%) developed HGD, or PC. Individuals with small cysts had a 1.5‐fold lower risk of developing WF or HRS (hazard ratio [HR] 0.7 [0.5–1.0], p = 0.03) than those with larger cysts but a similar risk of developing HGD or PC (p > 0.05). Slow growth was protective against the development of WF or HRS (HR 0.4 [0.2–0.6], p < 0.001) and HGD or PC (HR 0.04 [95% CI 0.02–0.12], p < 0.001). Individuals with small, stable sized cysts without baseline WF or HRS did not have a higher risk of HGD or PC than the general population (standardized incidence ratio [SIR] 1.13 [95% CI 0.01–6.30]).ConclusionCyst size < 15 mm and growth rate < 2.5 mm/year appear to be “reassuring” features associated with a negligible risk of developing WF or HRS and HGD or PC. For cysts with these characteristics—and without baseline WF or HRS—less intensive surveillance (than currently recommended) or even cessation may be appropriate.
Reply to “Dynamic Susceptibility Contrast MRI for Evaluation of Patients With High-Grade Glioma: Need for Multicenter Clinical Trial Validation”
Hu, Leland , Smits, Marion , Sundgren, Pia C. , Smits, Marion , Kaufmann, Timothy J. , Knutsson, Linda , Rapalino, Otto , Galldiks, Norbert , Cha, Soonmee

Mayo Clinic

American Journal of Roentgenology | May 28, 2025 | Volume: 226 | Issue: 1 | Pages: No page available

10.2214/ajr.25.33122 | PMID 40434165 Get It

Advanced Imaging in the Diagnosis and Response Assessment of High-Grade Glioma: AJR Expert Panel Narrative Review
Hu, Leland , Smits, Marion , Sundgren, Pia C. , Smits, Marion , Kaufmann, Timothy J. , Knutsson, Linda , Rapalino, Otto , Galldiks, Norbert , Cha, Soonmee

Mayo Clinic

American Journal of Roentgenology | March 13, 2024 | Volume: 224 | Issue: 1 | Pages: No page available

10.2214/ajr.23.30612 | PMID 38477525 Get It

Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group
Vollmuth, Philipp, Lohmann, Philipp , Smits, Marion , Veronesi, Michael C. , Albert, Nathalie L. , Hutterer, Markus , Vogelbaum, Michael A. , Wen, Patrick Y. , Galldiks, Norbert , Lohmann, Philipp , Smits, Marion , Soffietti, Riccardo , Weller, Michael , Kaufmann, Timothy J. , Vollmuth, Philipp, Langen, Karl‐Josef , Rudà, Roberta , Hattingen, Elke , Law, Ian G. , Soffietti, Riccardo , Wen, Patrick Yung , Tonn, Joerg-Christian

Mayo Clinic

Neuro-Oncology | March 11, 2024 | Volume: 26 | Issue: 7 | Pages: 1181-1194

10.1093/neuonc/noae049 | PMID 38466087 Get It

Abstract Brain tumor diagnostics have significantly evolved with the use of positron emission tomography (PET) and advanced magnetic resonance imaging (MRI) techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the Response Assessment in Neuro-Oncology (RANO) Group, the European Association of Neuro-oncology, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g. MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations, and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.
Author response: Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Vinayak, Shaveta , Sun, Tianyi , Kuderer, Nicole M. , Balmaceda, Nicole , Bilen, Mehmet Asım , Bindal, Poorva , Blau, Sibel , Bodin, Brianne E, Borno, Hala T. , Choi, Horyun, Deeken, John F. , Edwin, Natasha, Feldman, Lawrence , Flora, Daniel , Galsky, Matthew D. , Gonzalez, Cyndi J, Grivas, Petros , Gupta, Shilpa , Haynam, Marcy , Heilman, Hannah, Jhawar, Sachin R, Kaklamani, Virginia , Klein, Elizabeth J. , Koshkin, Vadim S. , Kulkarni, Amit , Kwon, Daniel H. , Lammers, Philip E. , Lathrop, Kate, Lewis, Mark A. , Lopes, Gilbert de Lima, Makower, Della , Mansoor, Abdul-Hai, Mashru, Sandeep H., McKay, Rana R. , Messing, Ian , Mico, Vasil, Nadkarni, Rajani, Namburi, Swathi, Nguyen, Ryan H, Nonato, Taylor K., Park, Kyu, Patel, Jaymin , Patel, Kanishka G. , Peppercorn, Jeffrey , Polimera, Hyma , Puc, Matthew , Reid, Sonya , Riess, Jonathan W. , Rivera, Donna R. , Russ, Atlantis Dawn, Schapira, Lidia , Shanahan, M Kelly, Smits, Melissa, Streckfuss, Mitrianna, Thompson, Michael A, Tolaney, Sara M. , Weissmann, Lisa B., Wilson, Grace, Wulff‐Burchfield, Elizabeth , French, Benjamin , Accordino, Melissa , Nagaraj, Gayathri , Khaki, Ali Raza , Aboulafia, David M. , Acoba, Jared David , Awosika, Joy A. , Bakouny, Ziad , Bao, Ting , Bashir, Babar , Berg, Stephanie , Castellano, Cecilia A. , Desai, Aakash , Friese, Christopher R. , Hershman, Dawn L. , Hwang, Clara , Jani, Chinmay , Jhawar, Sachin R, Joshi, Monika , Knox, Natalie, Labaki, Chris , Li, Xuanyi , Lyman, Gary H , Markham, Merry Jennifer , Nguyen, Ryan H, O’Connor, Tracey L. , Panagiotou, Orestis A. , Rao, Yuan James , Razavi, Pedram , Robson, Mark E. , Rose, Suzanne J. , Shah, Pankil , Shapiro, Lauren C. , Stover, Daniel G. , Tachiki, Lisa , Thompson, Michael A, Wotman, Michael T. , Mishra, Sanjay , Warner, Jeremy L. , Lustberg, Maryam B. , Shah, Dimpy P.

Mayo Clinic

No container title available | November 10, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.82618.sa2 Get It

Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164
Núñez, Nicolás A. , Kung, Simon , Voort, Jennifer L. Vande , Schak, Kathryn M. , Boehm, Stacey M., Carpenter, Brooke, Johnson, Emily K. , Malyshev, Grigoriy, Smits, Nathan , Adewunmi, Daniel O., Brown, Sarah K , Singh, Balwinder , Joseph, Boney , Vande Voort, Jennifer L , Singh, Balwinder , Joseph, Boney , Pazdernik, Vanessa , Smits, Nathan

Mayo Clinic

Pharmaceuticals | November 7, 2023 | Volume: 16 | Issue: 11 | Pages: 1571

10.3390/ph16111571 | PMID 38004498 Get It

In the original publication [...]
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Nagaraj, Gayathri , Vinayak, Shaveta , Sun, Tianyi , Kuderer, Nicole M. , Bakouny, Ziad , Balmaceda, Nicole , Bilen, Mehmet Asım , Bindal, Poorva , Blau, Sibel , Bodin, Brianne E, Borno, Hala T. , Castellano, Cecilia A. , Choi, Horyun, Deeken, John F. , Desai, Aakash , Edwin, Natasha, Feldman, Lawrence , Flora, Daniel , Galsky, Matthew D. , Gonzalez, Cyndi J, Grivas, Petros , Gupta, Shilpa , Haynam, Marcy , Heilman, Hannah, Jani, Chinmay , Jhawar, Sachin R, Kaklamani, Virginia , Klein, Elizabeth J. , Koshkin, Vadim S. , Kulkarni, Amit , Kwon, Daniel H. , Lammers, Philip E. , Lathrop, Kate, Lewis, Mark A. , Li, Xuanyi , Lopes, Gilbert de Lima, Makower, Della , Mansoor, Abdul-Hai, Mashru, Sandeep H., McKay, Rana R. , Messing, Ian , Mico, Vasil, Nadkarni, Rajani, Namburi, Swathi, Nguyen, Ryan H, Nonato, Taylor K., O’Connor, Tracey L. , Park, Kyu, Patel, Jaymin , Patel, Kanishka G. , Peppercorn, Jeffrey , Polimera, Hyma , Puc, Matthew , Rao, Yuan James , Reid, Sonya , Riess, Jonathan W. , Rivera, Donna R. , Rose, Suzanne J. , Russ, Atlantis Dawn, Schapira, Lidia , Shah, Pankil , Shanahan, M Kelly, Smits, Melissa, Streckfuss, Mitrianna, Thompson, Michael A, Tolaney, Sara M. , Weissmann, Lisa B., Wilson, Grace, Wulff‐Burchfield, Elizabeth , French, Benjamin , Lustberg, Maryam B. , Accordino, Melissa , Sun, Tianyi , Hwang, Clara , Puc, Matthew M , Mishra, Sanjay , Accordino, Melissa K , Desai, Aakash P , Bakouny, Ziad , Bilen, Mehmet A , Lustberg, Maryam , Khaki, Ali Raza , Aboulafia, David M. , Acoba, Jared David , Awosika, Joy A. , Bao, Ting , Bashir, Babar , Berg, Stephanie , Friese, Christopher R. , Hershman, Dawn L. , Hwang, Clara , Jhawar, Sachin R, Joshi, Monika , Knox, Natalie, Labaki, Chris , Lyman, Gary H , Markham, Merry Jennifer , Nguyen, Ryan H, Panagiotou, Orestis A. , Razavi, Pedram , Robson, Mark E. , Shapiro, Lauren C. , Stover, Daniel G. , Tachiki, Lisa , Wotman, Michael T. , Mishra, Sanjay , Warner, Jeremy L. , Shah, Dimpy P.

Mayo Clinic

eLife | October 17, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.82618 | PMID 37846664 Get It

Background: Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-19), especially among underrepresented racial/ethnic populations. Methods: This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with COVID-19 severity. Results: 1383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years, and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR per decade, 1.48 [95% CI, 1.32–1.67]); Black patients (aOR 1.74; 95 CI 1.24–2.45), Asian Americans and Pacific Islander patients (aOR 3.40; 95 CI 1.70–6.79) and Other (aOR 2.97; 95 CI 1.71–5.17) racial/ethnic groups; worse ECOG performance status (ECOG PS ≥2: aOR, 7.78 [95% CI, 4.83–12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63–3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20–2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66–3.04]); and active and progressing cancer (aOR, 12.5 [95% CI, 6.89–22.6]). Hispanic ethnicity, timing, and type of anti-cancer therapy modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and hospitalization rate for the entire cohort was 9% and 37%, respectively however, it varied according to the BC disease status. Conclusions: Using one of the largest registries on cancer and COVID-19, we identified patient and BC-related factors associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic patients experienced worse outcomes compared to non-Hispanic White patients. Funding: This study was partly supported by National Cancer Institute grant number P30 CA068485 to Tianyi Sun, Sanjay Mishra, Benjamin French, Jeremy L Warner; P30-CA046592 to Christopher R Friese; P30 CA023100 for Rana R McKay; P30-CA054174 for Pankil K Shah and Dimpy P Shah; KL2 TR002646 for Pankil Shah and the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE) and P30-CA054174 for Dimpy P Shah. REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. Clinical trial number: CCC19 registry is registered on ClinicalTrials.gov, NCT04354701 .